Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

Seung-Hoon Lee1*, Sang Won Jeon2*, Cheolmin Shin3, Chi-Un Pae4, Ashwin A. Patkar5, Prakash S. Masand6, Hyonggin An7, and Changsu Han8

1Department of Psychiatry, Veterans Health Service Medical Center, Seoul, Republic of Korea
2Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
3Department of Psychiatry, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
4Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
5Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
6Global Medical Education, New York, NY, USA
7Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea
8Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea

Psychiatry Investig 2022;19(4):268-280
https://doi.org/10.30773/pi.2021.0368

In the original publication, the affiliation of the fifth author, Ashwin A. Patkar, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA, was incorrect.
The corrected affiliation is as follows: Department of Advance Psychiatry, Rush University Medical Center, Raleigh, NC, USA.